USPSTF: Don't Routinely Screen Pregnant Women for Bacterial Vaginosis
By News Staff
3/4/2008
The guidance related to pregnant women at high risk for preterm delivery is considered an "I" statement, meaning that the USPSTF has concluded "that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined." Again, the task force found no direct evidence indicating that screening for bacterial vaginosis reduces adverse health outcomes in these women; and evidence from good-quality studies on the benefits of treating the condition is conflicting.
The USPSTF found only poor evidence regarding potential harms of screening for bacterial vaginosis in either group of pregnant women; studies in this area were lacking. However, task force members found fair evidence that false-positive results from screening asymptomatic women at low risk for preterm delivery can lead to harms associated with treatment. They found conflicting evidence regarding the harms of treating the condition in asymptomatic women at high risk for preterm delivery.
According to the "Clinical Considerations" section of the USPSTF recommendation statement, specific risk factors for preterm delivery include "African-American race or ethnicity," low body mass index, vaginal bleeding, previous preterm delivery, pelvic infection and bacterial vaginosis. Bacterial vaginosis, the most common lower genital tract syndrome among women of reproductive age, is most frequently seen in black women, women of lower socioeconomic status and those who previously have delivered low-birthweight babies.
Studies have documented an association between bacterial vaginosis and preterm delivery, and it is this epidemiologic evidence that for years had been used as a rationale for screening asymptomatic pregnant women for the disease -- despite the fact that as many as half of all cases resolve spontaneously during pregnancy.
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Pregnant Women
FDA Revises Diabetes Drug Prescribing Information
H1N1 Vaccine Availability Increasing Slowly
ACIP Supports 'Permissive Use' of Gardasil in Males
CDC Survey Shows Overall Gains in Teens' Immunization Rates
FDA Approves Gardasil for Males, Bivalent HPV Vaccine for Girls, Women
New USP Standards for Heparin Decrease Unit Dose Potency
H1N1 Vaccine Deliveries Begin This Week
Clinical Trial of H1N1 in Kids, Teens Shows Mixed Results
Physicians Should Use Caution With Tamiflu Dosages
Federal Health Officials Push H1N1 Vaccine for Adults, Health Workers
IOM: N95 Respirators Offer H1N1 Flu Defense for Health Personnel
CDC Updates Recommendations for Antiviral Use
CDC Updates Guidance on Ophthalmia Neonatorum Prophylaxis
CDC, FDA Study Reinforces Safety, Efficacy of Gardasil
H1N1 Vaccine Clinical Trials in Adults Free of Adverse Events
AAFP Launches Awareness Campaign for Pertussis Vaccination
H1N1 Vaccine Production Lagging Behind Expectations
FDA Issues Multiple Safety Alerts, Updates
Research Network Seeks Evidence to Support Collaborative Care








